PUBLICATIONS

1. Angappulige, D. H., Barashi, N. S., Pickersgill, N., Weimholt, C., Luo, J., Shadmani, G., Tarcha, Z., Rayamajhi, S., Mahajan, N. P.,  Andriole, G. L., Siegel, B. A., Kim, E. H., Mahajan, K, Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression. Journal of Nuclear Medicine 2024 0: p. jnumed.123.267301v1-jnumed.123.267301;DOI: https://doi.org/10.2967/jnumed.123.267301
2. Angappulige DH,  Mahajan N, and  Mahajan K^#*. Epigenetic Underpinnings of Tumor-Immune Dynamics in Prostate Cancer ImmuneSuppression. Trends in Cancer, 9 Feb 2024. https://authors.elsevier.com/sd/article/S2405-8033(24)00004-9.
3. Barashi NS, Li T, Angappulige DH, Zhang B,    O’Gorman H, Nottingham CU, Shetty AS, Ippolito JE, Andriole GL, Mahajan NP, Kim EH, and  Mahajan K. Prostate Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Show Lower Incidence of Prostate Cancer Development. Cancers 2024, 16(1), 213; https://doi.org/10.3390/cancers16010213 – 02 Jan 2024 
4. Nguyen D, Mahajan U, Angappulige, HD, Doshi A, Mahajan N, and Mahajan K*.  Amino terminal acetylation of HOXB13 regulates DNA damage  response in prostate cancer. 2024. Cancers 2024, 16(9), 1622; https://doi.org/10.3390/cancers16091622
5. Chouhan S,  Sridaran D,  Weimholt C,   Luo J, Li T, Hodgson MC, Santos LN,  Sommer SL, Fang B,   Koomen JM,   Seeliger M, Qu C, Yart A, Kontaridis MI, Mahajan K, Mahajan NP* SHP2 as a Primordial Epigenetic Enzyme Expunges Histone H3 pTyr-54 to Amend Androgen Receptor Homeostasis. Nature Communications 2024.https://doi.org/10.1038/s41467-024-49978-4

1. Nguyen  T,   Sridaran D,   Chouhan S,  Weimholt C,  Wilson A,  Luo J,   Li T, Koomen J, Fang B,  Putluri N, Sreekumar A,  Feng F,  Mahajan K, Mahajan N. Epigenetic Control of Androgen Production by Histone H2A Lys130 acetylation. Nature Communications 14, (1):3357, 2023. PMID: 37296155.
2. Sawant M, Wilson A,  Sridaran D,  Mahajan K,  O’Conor C,  Hagemann IS,   Luo J,   Weimholt  C, Roa JC, Wu X, Pandey A,  Mahajan N.      Epigenetic Reprogramming of Cell Cycle Genes Promotes Breast Cancer Resistance to CDK4/6 Inhibitor. Oncogene, Jul;42(29):2263-2277. 2023. 
3. Sridaran D, Bradshaw E, DeSelm C, Pachynski R, Mahajan K,  Mahajan NP. Prostate Cancer Immunotherapy: Improving Clinical Outcomes with a Multi-Pronged Approach. Cell Reports Medicine 4, 101199, October 17, 2023

1. Sridaran, D., Chouhan, S., Mahajan, K. et al. Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. Nat Commun 13, 6929 (2022). https://doi.org/10.1038/s41467-022-34724-5
2. Nguyen DT, Yang W, Renganathan A, Weimholt C, Angappulige DH, Nguyen T, Sprung RW, Andriole GL, Kim EH, Mahajan NP, Mahajan K. Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 Jul 18:CCR-21-3603. doi: 10.1158/1078-0432.CCR-21-3603. Online ahead of print.PMID: 35849143
3. Sawant  M, Mahajan K,  Renganathan A,  Weimholt C,  Luo J, Kukshal V,   Jez JM, Jeon MS, Zhang6, Tiandao B,  Fang B, Luo Y,   Lawrence NJ, Lawrence HR,   Feng FY, and  Mahajan NP*. Chronologically Modified Androgen Receptor in Recurrent Castration Resistant Prostate Cancer and its therapeutic Targeting. Science Translational Medicine, June 2022. DOI: 10.1126/scitranslmed.abg4132
4. Ghildiyal R,   Sawant, M ,  Renganathan A ,   Mahajan K ,   Kim EH,   Luo J ,  Dang HX, Maher CM, Feng F,  Mahajan NP *. Loss of long non-coding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistance, Cancer Research, 2022 Jan 1;82(1):155-168,  PMID: 34740892  PMCID: PMC8732311https://doi.org/10.1158/0008-5472.CAN-20-3845

4. Symptomatic benign prostatic hyperplasia with immune-enriched landscapes show lower incidence of prostate cancer development.   NB Gozal,  T Li, B  Zhang, C Nottingham, G Andriole, Mahajan K and E Kim The Journal of Urology, May 2022 Vol 27, No 5S, https://doi.org/10.1097/JU.0000000000002614.06

Kim EH, Cao D, Mahajan N, Andriole G and Mahajan K*. ACK1-AR-HOXB13 axis: Epigenetic Regulation of Lethal Prostate Cancer. Nucleic Acids Research Cancer, NAR Cancer, Volume 2, Issue 3, 2020. PMID: 32885168  PMCID: PMC7454006 https://doi.org/10.1093/narcan/zcaa018

Yao, J., Chen, Y., Nguyen, D.T. et al. The Homeobox gene, HOXB13, Regulates a Mitotic Protein-Kinase Interaction Network in Metastatic Prostate Cancers . Sci Rep 9, 9715 (2019). https://doi.org/10.1038/s41598-019-46064-4

1. Nerlakanti N, Yao J, Nguyen DT, Patel AK, Eroshkin AE, Lawrence HR, Ayaz M,. Kuenzi BM, Agarwal N, Chen Y, Gunawan S, Karim RM, Brendt N, Puskas J, Magliocco A, Coppola D, Dhillon J, Zhang J, Shymalagovindarajan S, Rix U, Kim Y, Perera R, Lawrence NJ, Schonbrunn E and Mahajan K*. Targeting the BRD4-HOXB13 Co-regulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2018. In press.
2. Mahajan NP*, Coppola D, Kim J, Lawrence H, Lawrence N and Mahajan K*, Blockade of ACK1/TNK2 signaling to squelch survival of Prostate Cancer Stem-like Cells.. Scientific Reports, 8(1):1954, 2018.

1. Mahajan K, Malla P, Lawrence HR, Chen Z, Kumar-Sinha C, Malik R, Shukla S, Kim J, Coppola D, Lawrence NJ, Mahajan NP. ACK1/TNK2 Regulates Histone H4 Tyr88- phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer.  Cancer Cell, Jun 12;31(6):790-803. 2017. PMID: 28609657
2. Mahajan N*, Pavani Malla, Amod Sarnaik, Jongphil Kim, Shari Pillon-Thomas, Jeffery Weber, and Mahajan K*. WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression. Oncotarget, 8(63):106352-106368, 2017.

1. Paranjape AN, R Soundararajan, S J Werden, R Joseph, J H Taube, H Liu, J Rodriguez- Canales, N Sphyris, I Wistuba, N Miura, J Dhillon,  N Mahajan,  Mahajan K, J T Chang,  M Ittmann, S N Maity, C Logothetis, D G Tang and S A Mani Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene 35, 5963–5976, 2016
2. Mahajan K* hPso4/hPrp19: A Critical Component of DNA Repair and DNA Damage Checkpoint Complexes. Oncogene, 35, 2279-2286, 2016.

1. Mahajan K* and Mahajan NP. Cross talk of Tyrosine Kinases with the DNA Damage Signaling Pathways. Nucleic Acids Research, 43(22):10588-601, 2015.
2. Lawrence HR, Mahajan K, Liu Y, Zhang D, Tindal N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP*, Lawrence NJ*. Development of novel ACK1 inhibitors using a fragment based approach. J Med Chem. 58(6):2746-2763, 2015.

1. Mahajan K*, Lawrence H, Lawrence NJ and Mahajan NP*. ACK1 Tyrosine Kinase Interacts with KDM3A to Regulate the Mammary Tumor Oncogene HOXA1. J Biol Chem, 289:28179-91, 2014
2. Mahajan K* and Mahajan NP*. ACK1/TNK2 tyrosine kinase: Molecular signaling and evolving role in cancer. Oncogene, 34(32):4162-7, 2014.
3. Mahajan K* and Mahajan NP*. AKT goes Cycling. Cancer Control, 21:239-4, 2014.

1. Mahajan K* and Mahajan NP*. Epigenetic Regulation of Core Histone Transcription: WEE1 as a Novel Epigenetic Modifier. Trends in Genetics, 29:394-402, 2013.
2. Mahajan K* and Mahajan NP*. Ack1 tyrosine kinase as an anticancer target in human cancer. Cancer Letters, 338:185-92, 2013.

1. Mahajan K, Fang B, Koomen J and Mahajan NP. H2B tyrosine 37-phosphorylation regulates expression of histone genes. Nature Structural & Molecular Biology, 19:930-937, 2012.
2. Mahajan K, Coppola D, Rawal B, Chen A, Lawrence H, Engelman RW, Lawrence NJ and Mahajan NP. Ack1/TNK2 inhibitor suppresses growth of Radioresistant Castration-Resistant Prostate Cancer. J Biol Chem, 287:22112-22, 2012.
3. Mahajan K* and Mahajan NP. PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics. Journal of Cellular Physiology, 227:3178-84, 2012.
4. Mahajan K, Coppola D, Lawrence H, Luo Y, Zhu W, Chen A, Lawrence NJ and Mahajan NP. Ack1 Tyrosine Kinase Activation Correlates with Pancreatic Cancer Progression. American Journal of Pathology, 180:1386-93, 2012.

1. Mahajan K and Mahajan NP Shepherding AKT and Androgen Receptor by Ack1 tyrosine kinase. J Cell Physiology, 224:327-33, 2010.
2. Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schönbrunn E, Sebti SM, Earp HS, Mahajan NP. Ack1 Mediated AKT/PKB Tyrosine 176 Phosphorylation Regulates Its Activation. PLoS One.5(3): e9646, 2010.
3. Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu W, Chen YA, Lawrence NJ, Mahajan NP. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate, 70 (12);1274-85, 2010.

1. Anuradha S., Tripathi P., Mahajan, K., Muniyappa, K. Meiosis-specific yeast Hop1 protein promotes pairing of double-stranded DNA helices via G/C isochores. Biochemical and Biophysical Research Communications, 28;336(3):934-41, 2005.
2. Mahajan, K* and Mitchell, B.S. Role of human Pso4 in Mammalian DNA Repair and Association with Terminal Deoxynucleotidyl Transferase. Proc. Natl. Acad. Sci. USA. 100:10746-10751, 2003.
3. Mahajan, K, McElhinny, S,A,N., Mitchell, B. S., and Ramsden, D.A. Association of DNA Polymerase µ (pol µ) with Ku and Ligase IV: Role for pol µ in End-Joining Double-Strand Break Repair. Molecular and Cellular Biology, 22:5194-5202, 2002.
4. Mahajan, K, Gangi-Peterson, L., Sorscher, D.H., Wang, J, Gathy, K.N., Mahajan, N.P., Reeves, W.H., and Mitchell, B.S. Association of Terminal deoxynucleotidyl transferase with Ku. Proc. Natl. Acad. Sci. USA. 96:13926-13931, 1999.